Unkart Edward W 4

What Happened

• Director Edward W. Unkart reported dispositions on 2026-06-11 totaling 109,000 underlying shares (multiple derivative cancellations: 12,000; 6,000; 10,000; 7,000; 7,000; 7,000; 10,000; 10,000; 10,000; 30,000).
• These were derivative (option) dispositions to the issuer in connection with the merger by Chiesi Farmaceutici S.p.A.; the company was acquired for $27.00 per common share and the merger became effective June 11, 2026.
• Per the merger terms, in‑the‑money unexercised options were accelerated/vested (where applicable) and cancelled in exchange for a cash payment equal to (Merger Consideration $27.00 − option exercise price) × number of option shares. Options with exercise prices ≥ $27 were cancelled for no consideration.

Key Details

• Transaction date: 2026-06-11 (filing accession 0001306267-26-000002); filing date matches transaction date (appears timely).
• Transaction type: Disposition to issuer (derivative cancellation under Merger Agreement).
• Total underlying shares affected: 109,000.
• Merger consideration: $27.00 per share (cash tender and subsequent merger); reported Form 4 shows N/A for per-share price since cash value depends on each option's strike.
• Footnotes: F1 (Merger Agreement and cash tender/merger effective 6/11/2026); F3 (in‑the‑money options vested and cashed out as described); F2/F4 reference vesting status (one option noted fully vested; another vests monthly over 12 months).
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• These were not open-market sales but a corporate-action cash-out of outstanding options due to an acquisition; proceeds depend on each option’s exercise price, not simply $27 × shares.
• Such filings reflect transaction mechanics of a merger (acceleration/cash settlement of options) rather than an insider trading decision; they do not necessarily signal bullish or bearish sentiment by the insider.